CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
Status:
Unknown status
Trial end date:
2018-03-30
Target enrollment:
Participant gender:
Summary
Approximately 21 subjects with amyotrophic lateral sclerosis (ALS) will be randomized (6 to
1) to receive by mouth seven morning doses of CC100 or placebo for 7 days. Subjects are
required to stay in the Clinic for approximately 9 hours following the first and last dose.
Subjects will also have a mid-week clinic visit and will be contacted by phone within 3 to 5
days after the last dose.
Funding Source - FDA OOPD